| FACIAL AESTHETICS | ARTICLE Approximately every 6 months,
the mimetic wrinkles of the upper third of the face were treated with
BoNT A using Incobotulinumtoxin A, reconstituted in 1.25 cc, sterile, 0.9% unpreserved saline.
severe wrinkles) at maximum contraction Infraorbital hollowness was MS 4 (very severe hollows),
with upper and lower dermatochalasis and protrusion of lower eyelid fat pad. The nasiolabial folds were marked at MS 4 (very severe fold), the upper mid-face at MS 3 (severely sunken upper cheek), lower mid-face at MS 4 (very severely sunken lower cheek), oral commissures at MS 4 (very severe downturn), upper-lip rhytides at MS 2 (moderate wrinkles), upper and lower lip volume at MS 3 (thick), and the jawline at MS 3 (severe sagging). There was also prominent volume loss to the mid-face
(MS 3–4) and a loss of contour to the jawline (MS 3), as well as static wrinkles (MS 2–4) and severe mimetic wrinkles (MS 2–4). The patient also had signs of actinic elastosis.
Therapy In this article the author showcases the aesthetic treatments that this patient received over the past 7 years, from 2005 to date.
Figure 4 Treatment to the nasolabial folds with dermal filler, (A) before treatment and (B) directly after treatment. This demonstrates the direct filling technique; linear threading with a short, sharp 27G needle, injecting Radiesse®, 0.5 cc per side, premixed with Lidocaine 1%
NEW!
STERiGLIDE The Cannula That Glides.
• New tip design, improved flexibility and proprietary surface treatment for
optimal control and precision.
• Lowest extrusion force and nearest to tip filler delivery.
• Clear side port marking on safety hub.
• Entry-hole needles included in same safe and convenient capsule packaging.
TSK LABORATORY EUROPE B .V.
www.tsklab.com |
europe@tsklab.com Made in Japan
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84